Press Releases

First Previous Next End

August 18, 2015

Pfizer, Provectus Biopharmaceuticals Awarded US Patent Protecting Use of PV-10 as Part of Combination Therapy for Cancer

Provectus today announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

August 6, 2015

Provectus Biopharmaceuticals Reports Second Quarter 2015 Financial Results

Provectus today announced its results of operations and financial condition for the second quarter ended June 30, 2015.

July 22, 2015

Provectus Biopharmaceuticals Will Hold Its 2015 Second Quarter Business Update Conference Call on Thursday, August 6, 2015, at 4 PM Eastern Daylight Time

Provectus announced today that it will hold its 2015 second quarter business update conference call at 4 pm Eastern Daylight Time on Thursday, August 6, 2015.

July 15, 2015

Provectus Biopharmaceuticals, Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search for Agreement on PV-10 Use in China

Provectus announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.

July 6, 2015

Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Provectus announced today that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.

July 2, 2015

Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China

Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").

July 2, 2015

Provectus Biopharmaceuticals' Data on PV-10 for Chemoablation of Liver Cancers Presented at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).

June 26, 2015

AAPI Honors Provectus Biopharmaceuticals During 33rd Annual Convention and Scientific Assembly

The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.

June 26, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Treatment for Melanoma Presented at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.

June 25, 2015

Provectus Biopharmaceuticals' Poster Presentation Displayed on Phase 3 Study of PV-10 at 5th European Post-Chicago Melanoma / Skin Cancer Meeting

Provectus announced that its poster presentation titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma" is on display at the 5th European Post-Chicago Melanoma / Skin Cancer Meeting in Munich, Germany.

June 24, 2015

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Congress on Gastrointestinal Cancer

Provectus announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver" to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at: http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085

June 24, 2015

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering

Provectus announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.

June 22, 2015

Provectus Biopharmaceuticals Retains PharmaHEALTHLabs to Facilitate Investigator Advisory Board Meeting During 11Th Brazilian Melanoma Conference

Provectus announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.

June 19, 2015

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $13.1 Million

Provectus today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.

June 18, 2015

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Provectus today announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock, subject to market and other conditions, in an underwritten public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.

June 16, 2015

Abstract on Provectus Biopharmaceuticals' PV-10 in Colon Cancer Models Published by Society of Surgical Oncology

Provectus announced that the Society of Surgical Oncology (SSO) has published an abstract describing preliminary research into use of the Company's investigational agent, PV-10, in murine models of colon cancer.

June 11, 2015

Provectus Biopharmaceuticals to Present at 2015 BIO International Convention in Philadelphia

Provectus announced today that it will present at the 2015 BIO International Convention on Tuesday, June 16, at 10:45 am Eastern.

June 2, 2015

Provectus Biopharmaceuticals Retains Allison+Partners as New Media Relations Consultant

Provectus announced today that it has retained Allison+Partners as its new media relations consultant.

June 1, 2015

Provectus Biopharmaceuticals' Data on PV-10 as Intralesional Treatment of Melanoma Presented at 2015 American Society of Clinical Oncology Annual Meeting

Provectus announced today that Dr. Sanjiv Agarwala, chief of medical oncology and hematology at St. Luke's Cancer Center in Bethlehem, Pennsylvania, and professor of medicine at Temple University School of Medicine in Philadelphia, presented data on PV-10 as an investigational intralesional treatment of melanoma at the 2015 American Society of Clinical Oncology's Annual Meeting on May 31, 2015.

May 28, 2015

Provectus Biopharmaceuticals' Abstract on Liver Cancer Accepted for Poster Presentation at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

Provectus announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company's abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.

First Previous Next End